Sinovac Amends Shareholder Rights Plan
February 22 2023 - 6:00AM
Business Wire
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA),
a leading provider of biopharmaceutical products in China, today
announced that its board of directors has amended its shareholder
rights plan. The amendment extends the expiration date of the plan
from February 22, 2023 to February 22, 2024.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based
biopharmaceutical company that focuses on the R&D,
manufacturing, and commercialization of vaccines that protect
against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19,
enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD),
hepatitis A, varicella, influenza, poliomyelitis, pneumococcal
disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in
more than 60 countries and regions worldwide. The hepatitis A
vaccine, Healive®, passed WHO prequalification requirements in
2017. The EV71 vaccine, Inlive®, is an innovative vaccine under
"Category 1 Preventative Biological Products" and commercialized in
China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio
vaccine (sIPV) and varicella vaccine were prequalified by the
WHO.
SINOVAC was the first company to be granted approval for its
H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese
government's vaccination campaign and stockpiling program. The
Company is also the only supplier of the H5N1 pandemic influenza
vaccine, Panflu®, to the Chinese government stockpiling
program.
SINOVAC continually dedicates itself to new vaccine R&D,
with more combination vaccine products in its pipeline, and
constantly explores global market opportunities. SINOVAC plans to
conduct more extensive and in-depth trade and cooperation with
additional countries, and business and industry organizations.
For more information, please visit the Company’s website at
www.sinovac.com.
Safe Harbor Statement
This press release may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as “will,” “expects,” “anticipates,” “future,”
“intends,” “plans,” “believes,” “estimates” and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements. In particular, the outcome
of any litigation is uncertain, and the Company cannot predict the
potential results of the litigation it filed or filed against it by
others. Additionally, the triggering of a shareholder rights plan
is nearly unprecedented, and the Company cannot predict the impact
on the Company or its stock price as a result of the trigger of the
rights plan.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230222005433/en/
Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871 or
+86-10-5693-1897 Fax: +86-10-6296-6910 Email: ir@sinovac.com
ICR Inc. Bill Zima U.S.: 1-646-308-1707 Email:
william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024